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diatric patients who received HSCT were identiﬁed. Among
these 1023 (7.4%) children were identiﬁed to have the
diagnosis of RSV. Out of 1023 children with RSV, 19%
required ICU care and 14% required mechanical ventilation.
Overall, the trend of RSV diagnosis was stable in our cohort
(Figure 1). The demographic characteristics, risk factors
and outcome of these children with and without RSV are
shown in Figure 2. RSV was signiﬁcantly associated with
allogeneic HSCT (p¼<0.001), CMV (p¼<0.001), fungal
infection (p¼<0.001) and GVHD (p¼<0.001). Prophylactic
Pavilizumab was associated with lower risk of RSV only
in patients <1 year of age (24% vs. 76%, p¼<0.0001). The
mortality was signiﬁcantly higher in patients with RSV
compared to those without (18.6% vs. 11.4%, p <0.001).
However, there was no difference in median time (days)
to mortality following HSCT in patients with or without
RSV (1427 [615, 2769] vs. 1554 [613, 3038], p¼0.1).
Multivariate logistic regression analysis of age, gender,
HSCT type, CMV, GVHD, concurrent viral and bacterial
respiratory infections, Pavilizumab, IVIG, Respigam and
Ribavirin showed only older age i.e. 10 years at the time
of HSCT [HR 2.17 (1.35, 3.48), p¼<0.001], GVHD [HR 1.36
(1.01, 1.84), p¼0.041] were associated with increased
mortality whereas the use of IGIV [HR 0.74 (0.54, 0.99),
p¼0.049] was protective in patients with RSV (Figure 3).
Conclusions: Ours is the largest cohort of RSV following
HSCT in children with the prevalence of 7.4%. The mortality
in our pediatric cohort is 18.6% which is similar to previ-
ously publishes case series. Older patients, GVHD were
associated with increased mortality whereas Pavilizumab
not associated with improved survival in our study. Further
studies are needed to explore effective RSV prophylactic
strategies and the use of novel therapies to optimize the
outcome.307
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Background: Sickle cell disease (SCD) is a state of chronic
inﬂammation and hypercoagulability. Previous studies have
demonstrated that patients with SCD experience higher rates
of perioperative complications when compared to normal
patients. Although SCD is considered a hypercoagulable
disease, intra-operative bleeding has been reported as a
signiﬁcant complication. Patients with SCD who are
admitted for surgical procedures often are found to have
prolonged prothrombin times (PT), which may contribute to
the risk of bleeding. Matched-related donor (MRD) bone
marrow transplant (BMT) offers a cure for patients with SCD.
Matched-related donors often have sickle cell trait (SCT). We
anecdotally observed multiple MRD with SCT and mild pro-
longation of the PT. This prompted a systematic examination
of a series of MRD for coagulation values, SCT status, and the
incidence of bleeding complications with the bone marrow
harvest.
Methods: Retrospective chart review of MRD BMT donors for
sickle cell disease between 1/2005-10/2014 to compare PT,
partial prothrombin times (PTT), international normalized
ratio (INR), and the incidence of bleeding complications indonors with and without SCT. Mann-Whitney and Fisher’s
Exact test were used for statistical analyses.
Results: Twenty-ﬁve donors were included in the analysis.
Median age of donors was 9.8 years (range 2.6-25.3). None of
the donors had bleeding complications with the bone
marrow harvest. Sixteen of the twenty-ﬁve (64%) donors had
SCT. Of the 16 patients with SCT, 5(31%) had a prolonged PT,
whereas only 1/9 (11%) of patients without SCT had a pro-
longed PT. Although the trend was suggestive, the sample
size was too small to show that the difference was statisti-
cally signiﬁcant (p¼0.36). There was also no signiﬁcant dif-
ference in INR or PTT. The average PT in SCT patients with
prolonged PT was 15.1 seconds (14.2-16.1), and average INR
was 1.23 (1.16-1.33).
Conclusions: Our series suggests that patients with SCT tend
to have prolonged PT when compared to normal controls.
However, despite the prolongation in PT, none of the donors
experienced signiﬁcant perioperative complications,
including bleeding. The cause of this prolongation in PT in
patients with SCT remains uncertain, but may be a result of
low levels of sickling in the kidneys, mild liver dysfunction,
or vitamin K deﬁciency. A planned multi-center study
examining coagulation values and bleeding complications in
donors with and without sickle cell trait should allow
conﬁrmation of the ﬁnding that there is no increased risk of
perioperative bleeding in these donors and that donors with
SCT have a statistically signiﬁcant increase in the incidence of
prolonged PT. That determination would be timely given the
increasing numbers of patients being transplanted for SCD,
many of whose related donors will have the trait.308
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Background: Adoptive immunotherapy using virus-speciﬁc
cytotoxic T-lymphocyte (VSTs) products has been successful
in restoring antiviral immunity after hematopoietic stem cell
transplantation (HSCT), and has been used to treat patients
with primary immunodeﬁciency (PIDD). Theymay also be an
invaluable salvage therapy for refractory viral infections
prior to HSCT. VST can be produced from virus-exposed do-
nors in as little as 10-14 days, and new protocols allow VST
production from virus-naïve donors in 4-5 weeks.
Objective: To evaluate the clinical efﬁcacy of VSTs for the
prevention and treatment of CMV, EBV, and Adenovirus in
patients with PIDD both before and after HSCT.
Design/Methods: VSTs were cultured from HSCT donors
using peptide pulsed antigen presenting cells and cytokines.
VSTs were tested for speciﬁcity and non-alloreactivity via
IFN-g ELISpot and cytotoxicity assays. Patients were followed
for 45 days following infusion for toxicity monitoring and for
>6 months for antiviral response.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S230Results: Five patients with PIDD who underwent HSCT were
recruited to date, and two have been infused with VSTs at
5x10E6 cells/m2/dose. The manufactured VSTs had a CD4+ T-
cell predominance with detectable antiviral activity against
CMV pp65/IE1, EBV-LMP2/EBNA1, and Adv-Hexon/Penton
epitopes based on IFN-g ELISpot assays. All VSTs were non-
alloreactive in chromium release assays utilizing allogeneic
PHA blasts as targets (<5% lysis at effector:target ratios of
20:1). The ﬁrst patient was treated for CMV viremia which
was refractory to ganciclovir and foscarnet following hap-
loidentical HSCT for SCID. Following two VST infusions, the
CMV load reduced from >1,000,000 to<1000 copies/ml. The
second patient was treated for CMV viremia after matched
sibling HSCT for MHC-II deﬁciency, and had viral clearance of
CMV within 1-month post-VST infusion. One patient devel-
oped Grade I skin GVHD post VSTs which resolved within 1
week and was associated with the tapering of immune
suppression.
Conclusions: VSTs are safe and effective for control of viral
infections in patients with PIDD following HSCT. We plan
further evaluation of virus-speciﬁc CTL for patients with
PIDD both before and after HSCT.309
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Background: Inherited bone marrow failure syndromes
(IBMFS) include genetic disorders with hematopoietic
cytopenias due to mutations in genes supporting normal
hematopoiesis. Transformation to myeloid leukemia or
myelodysplastic syndrome occurs in 4-25% by adulthood.
Allogeneic hematopoietic cell transplantation (HCT) is cura-
tive but has been largely limited to sibling donor HCT due to
toxicities of alternative donor transplants. The development
of successful HCT strategies is necessary in this setting to
beneﬁt more patients. This includes optimizing transplant
conditioning, reducing mortality, late effects, and GVHD so
HCT can beneﬁt more patients.
Hypothesis: A reduced intensity conditioning regimen (RIC)
and HCT from matched marrow or matched/one-antigen
mismatched cord will result in high overall survival (OS) and
event-free survival (EFS) in patients (<21 years) with IBMFS
(excluding Fanconi Anemia).
Methods: IBMFS patients (3 Diamond-Blackfan Anemia,
1 Congenital Dyserythropoietic Anemia, 1 Shwachman-
Diamond Syndrome, 2 Congenital Amegakaryocytic
Thrombocytopenia, 1 Congenital BM Failure, 1 X-linked
Thrombocytopenia, 1 Severe Congenital Neutropenia, 1 X-
Chromosome Deletion) received alemtuzumab intrave-
nously for 3 days (dose 33 mg if <10kg; 45 mg if >10kg)
(day -21 to -19), ﬂudarabine (30 mg/m2/day) (day -8 to -4)
and melphalan (140 mg/m2) on day -3. All received acalcineurin inhibitor as GVHD prophylaxis. Marrow re-
cipients received short course methotrexate and steroids,
and cord recipients received mycophenolate.
Results: Eleven patients between 2 months and 14 years of
age (median 23 months) underwent HCT. Nine were from
unrelated donors; ten received BM; one received UCB. Ten
had full donor chimerism by 30 days. OS and EFS were 82%
with median follow up of 62 months (range 12-186). Two
deaths (BM recipients for DBA and Congenital BMF) at day 45
and 346 were due to aGVHD and graft rejection followed by
mortality after a second transplant respectively. The cumu-
lative incidence of acute (grade II-IV) and chronic GVHD was
9 and 0% respectively. Eight of the 9 survivors had success-
fully discontinued systemic immunosuppression by one year
post HCT. Robust immune reconstitution was noted at 1 year
in survivors.
Conclusions: This RIC regimen was tolerated well by this
very young recipient group. The regimen had a high success
rate (also previously described in HCT for Shwachman-Dia-
mond syndrome: Bhatla, BMT 2008) and is expected to have
fewer late toxicities. Though the numbers are small, out-
comes are encouraging in these rare disorders supporting a
HCT consideration early during the course of the disease
prior to marrow related complications.310
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Overview: BK viremia (BKV) occurs in >15% of patients after
hematopoietic cell transplantation (HCT), primarily in asso-
ciation with cystitis. It is unknown if BK virus-induced renal
disease (polyomavirus nephropathy, PVN) is also common
after HCT. Kidney biopsy is the gold standard for the diag-
nosis of PVN but has a high risk of bleeding after HCT. The
non-invasive urinary PV-Haufen test is sensitive/speciﬁc for
PVN in renal transplant recipients with positive/negative
predictive values >90%. PV-Haufen are cast-like BK aggre-
gates that form in virally injured kidney tubules, are shed,
and can easily be detected in urine samples. PV-Haufen do
not form in the bladder and are not seen in cystitis without
PVN. In this pilot study, we used the PV-Haufen test for the
ﬁrst time in children after HCT to screen for PVN.
Methods: Subjects with BKV (potential cases) and without
BKV (presumed controls) after allogeneic HCT were selected
from cohorts at Cincinnati Children’s Hospital and the Chil-
dren’s Hospital of Philadelphia. Urine samples (10-25 ml)
were ﬁxed in a 1:1 ratio with 4% paraformaldehyde, stored at
4C, and tested for urinary PV-Haufen using negative staining
electron microscopy (JASN, 2009, 20(2):416-27). Urine sam-
ples containing 1 PV-Haufen were classiﬁed as positive,
supporting a diagnosis of PVN.
Results:We tested 20 voided urine samples from 15 subjects
(median age 11.5 years, range 5.2-29.8; median HCT follow
up time 306 days, range 87-815). Urine Haufen (Fig 1) were
